On May 2, 2024, Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, announced the close of a $103 million Series A financing co-led by Novo Holdings and MPM BioImpact, with participation from Arkin Bio Capital, Mitsui & Co. Global Investment, Plaisance Capital, FemHealth Ventures, and Palo Santo. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.

 

Reunion Neuroscience is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with underserved mental health disorders. The new financing will support a Phase 2 clinical trial for RE104 in postpartum depression (PPD) and expansion into other psychiatric indications of high unmet need, including adjustment disorder in cancer (ADC).

 

The Wilson Sonsini team that advised Novo Holdings on the transaction included:

 

Corporate

Dan Koeppen

Kassandra Castillo

Karl Kobylecki

Trevor Dorne

Patents and Innovations

Mike Hostetler

Valentin Zunic

TJ O’Connor

 

Technology Transactions

Miranda Biven

Nguyen Pham

Jordin Wilcher

 

National Security

Stephen Heifetz

Jonathan Davey

 

For more information, please see Reunion Neuroscience’s press release.